A study to assess the safety and tolerability of next-generation neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) therapy. NEXTGEN-TIL-ACT
VHIO20001
Phase 1 other active
Quick answer
A study to assess the safety and tolerability of next-generation neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) therapy. NEXTGEN-TIL-ACT for Advanced epithelial tumors and immune checkpoint blockade (ICB) resistant solid tumors is a Phase 1 program (other) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- Advanced epithelial tumors and immune checkpoint blockade (ICB) resistant solid tumors
- Phase
- Phase 1
- Modality
- other
- Status
- active